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Jeroen J. Bax21, and Alberico L. Catapano22
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Preamble
The first randomized controlled data from cardiovascular out-
comes trials with proprotein convertase subtilisin/kexin type 9
(PCSK9) inhibitors have now been reported.1,2 This ESC/EAS
Task Force met to consider the impact on practical guidance for
the use of these novel agents. This updated clinical guidance pro-
vides novel clinical decision algorithms when considering a PCSK9
inhibitor, and monitoring treatment efficacy to statin, ezetimibe
and PCSK9 inhibitor. Gaps in knowledge for PCSK9 inhibition are
also discussed.
Introduction
The Further Cardiovascular Outcomes Research With PCSK9
Inhibition in Subjects With Elevated Risk (FOURIER) trial (with evo-
locumab, a fully human monoclonal PCSK9 antibody) in 27 564 pa-
tients with atherosclerotic cardiovascular disease (ASCVD) was the
first to be completed.1 The Evaluation of Bococizumab in Reducing
the Occurrence of Major Cardiovascular Events in High Risk Subjects
(SPIRE)-1 and -2 trials were, however, stopped early following termi-
nation of bococizumab development due to effects specific to this an-
tibody (Box 1).2,3 In FOURIER, lowering of low-density lipoprotein
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cholesterol (LDL-C) levels by 59% (from 2.4 mmol/L to 0.78 mmol/
L) significantly reduced the risk of major cardiovascular events (abso-
lute event rates 9.8% vs. 11.3% on placebo over 2.2 years, relative
risk reduction of 15%). The clinical benefit of PCSK9 inhibitor treat-
ment was due to reduction of nonfatal events, largely driven by re-
duction in myocardial infarction (MI) and coronary revascularization.
This benefit was generally consistent across all major patient sub-
groups, including age, sex, and type of clinical presentation of ASCVD
[coronary artery disease (CAD) with history of MI, ischaemic stroke
and symptomatic peripheral arterial disease (PAD)], and accrued
over time.1 Compared with the Cholesterol Treatment Trialists’
(CTT) Collaboration for cardiovascular benefit per mmol/L reduc-
tion in LDL-C, which is based on average response over 5 years on
statin therapy, the observed benefit in FOURIER was shown to fall
below the regression line. When adjusted for duration of treatment,
however, as the benefit of a cholesterol lowering therapy in the first
year of treatment is less than in the following years, the results from
FOURIER were superimposable with those observed with statin
therapy (Figure 1).4 Evidence from studies involving variants in the
genes encoding PCSK9 and 3-hydroxy-3-methyl-glutaryl-CoA
(HMGCoA) reductase provides further support for the concept that
a similar risk reduction per unit LDL-C reduction is to be expected.5
Insights from these trials reinforce that the key determinants of clini-
cal benefit are the absolute cardiovascular risk, the absolute magnitude
of LDL-C reduction, and the absolute LDL-C level. In all trials, patients
were at very high risk as defined by guidelines,6,7 with a history of clinical
ASCVD (either MI, stroke, or symptomatic PAD) and additional cardio-
vascular risk factors, including, in the SPIRE trials, clinically diagnosed fa-
milial hypercholesterolaemia (FH).1,2 Patients had elevated LDL-C
levels despite maximally tolerated lipid lowering therapy (the vast ma-
jority received high to moderate intensity statin therapy). In SPIRE-2,
patients had higher LDL-C levels (mean at baseline 3.4 mmol/L or 133
mg/dL vs. 2.4 mmol/L or 90 mg/dL in FOURIER and SPIRE-1).1,2
Thus, despite progressive attenuation of LDL-C lowering with bococi-
zumab due to the formation of neutralizing antibodies,3 there was still
significant clinical benefit in SPIRE-2 within 12 months (absolute event
rates for major cardiovascular events 3.32% vs. 4.19% on placebo, rela-
tive risk reduction of 21%, P = 0.02). SPIRE-1 did not reveal a significant
difference in cardiovascular events, however, as patients had lower
LDL-C levels and the duration of treatment was short (7 months).2
Two key issues are pertinent when interpreting the results of
FOURIER. The first issue relates to the rather short duration of the trial.
It is important to emphasize that as the trial was event- and not time-
driven the short duration was due to trial design. Allowing for a possible
lag in treatment benefit, as seen in the statin trials, FOURIER planned
for a median duration of 43 months to allow for accrual of 1630 key
secondary end points (a composite of cardiovascular death, MI, or
stroke), which would provide 90% power to detect a relative reduction
of at least 15% for this endpoint.8 In reality, the observed event rate
was higher and therefore the trial was completed after a median of
26 months at which time 1829 key secondary endpoints had occurred.1
The second issue relates to the lack of significant benefit on cardio-
vascular and all-cause mortality. As noted above, the FOURIER data
show that the predominant effect of PCSK9 inhibition was preven-
tion of non-fatal cardiovascular events, mainly driven by MI and coro-
nary revascularization; fatal MI or stroke accounted for only 5–10%
of all MI or stroke events.1 These findings are consistent with trials
evaluating high- vs. low-dose statin therapy, none of which showed
reduction in cardiovascular death. Added to this, a meta-analysis of
four high- vs. low-dose statin trials indicated a reduction mainly in
non-fatal cardiovascular events in patients allocated to the high-dose
regimen.9 Moreover, while reduced mortality was observed in earlier
statin trials (e.g. the Scandinavian Simvastatin Survival Study, 4S),10
this was only seen after prolonged treatment and not after 2.2 years
against a background of contemporaneous, predominantly high-dose
statin therapy as in FOURIER. It will therefore be of great interest to
see whether longer follow-up of patients treated with a PCSK9 inhib-
itor results in reduction in mortality.
Together with definitive evidence that LDL is causal for ASCVD,11
the results of the FOURIER and SPIRE trials constitute a key step for-
ward in addressing unanswered questions about PCSK9 inhibition in
the previous Task Force document.12 It should, however, be noted
that while the FOURIER and SPIRE-1 and SPIRE-2 protocols permit-
ted enrolment of patients with mild to moderate chronic kidney dis-
ease, there are currently no available data on which to base
recommendations for the use of PCSK9 inhibitors. Furthermore,
while there is reassurance regarding the safety of very low LDL-C lev-
els that can be attained on PCSK9 inhibitor therapy,13,14 this Task
Force recognizes that these data are limited in large part to the short
observation period of the currently available clinical trials.
Box 1 Key reasons for termination of bococizumab
The development of bococizumab was discontinued by Pfizer in late 2016.a The key reasons for this were a high level of immunogenicity and wide vari-
ability in the low-density lipoprotein cholesterol (LDL-C) lowering response.
• Immunogenicity: In statin-treated patients, PCSK9 inhibition with bococizumab reduced LDL-C levels by 55–60% in the short-term, but this effect was at-
tenuated over time in 10–15% of patients due to the development of antidrug antibodies. It is important to note that this effect was specific to bococi-
zumab, a partially humanized monoclonal antibody, which is characterized by substitution of rodent DNA sequences for <5% of human DNA
sequences. It is thought that this substitution may have directly affected the immunogenicity of the antibody. This effect has not been reported for either
evolocumab or alirocumab, which are fully human monoclonal antibodies. This immunogenicity may also explain the higher rate of injection site reac-
tions (10%) observed with bococizumab compared with either alirocumab or evolocumab (<5%).
• Variability in LDL-C lowering response: Irrespective of the presence or absence of antidrug antibodies, there was wide individual variability in the LDL-C
lowering response with bococizumab; about 1 in 10 showed no reduction in LDL-C levels.
aPress release Tuesday, 1 November 2016. Pfizer Discontinues Global Development of Bococizumab, Its Investigational PCSK9 Inhibitor.
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Figure 1 Cholesterol Treatment Trialists’ Collaboration regression lines by duration of statin therapy. The lines represent the average expected
proportional risk reduction for any given absolute low-density lipoprotein cholesterol (LDL-C) reduction by duration of statin therapy calculated us-
ing data from the Cholesterol Treatment Trialists’ (CTT) Collaboration meta-analysis of statin trials. The red line represents the expected clinical
benefit of statins after 1 year of treatment, the blue line represents the expected clinical benefit after 2 years of treatment, the green line represents
the expected clinical benefit after 3 years of treatment, and the black line represents the expected clinical benefit after 4 or more years of treatment.
The lines are calculated from the CTT data (see Panel below). Column 2 of this Panel shows the proportional risk reduction per mmol/L reduction in
LDL-C observed during each year of treatment with a statin. The proportional risk reduction per mmol/L reduction in LDL-C for any duration of sta-
tin therapy is calculated as an inverse-variance weighted meta-analysis of the effect of statin therapy during each year of treatment up to and including
the year of interest (Panel, column 4). The CTT regression line for each duration of therapy is then plotted as a line through this estimate of the pro-
portional risk reduction per mmol/L reduction in LDL-C for each duration of therapy with each line forced to pass through the origin (using the same
methods as used by the CTT Collaborators). The black boxes represent the results of trials (CARE, WOSCOPS, HPS, and 4S) that had an average
duration of follow-up of 5 years or more, while the blue boxes represent the results of trials (PROVE-IT and FOURIER) that had an average duration
of follow-up of approximately 2 years. The figure shows that the point estimate from FOURIER (with a median follow-up of 2.2 years) is superimpos-
able on the blue CTT regression line corresponding to the effect of 2 years of treatment with a statin.
....................................................................................................................................................................................................................
Panel Proportional risk reduction per mmol/L reduction in LDL-C based on CTT Collaboration meta-analysis of
statin trials
Year of treatment CTT hazard ratio (95% CI) per mmol/L
reduction in LDL-C during each
year of treatment
Cumulative duration
of treatment (years)
CTT hazard ratio (95%) per mmol/L
reduction in LDL-C for each
duration of treatment
0–1 0.88 (0.84–0.93) 1 0.88 (0.84–0.93)
1–2 0.77 (0.73–0.82) 2 0.83 (0.80–0.86)
2–3 0.73 (0.69–0.78) 3 0.80 (0.77–0.83)
3–4 0.72 (0.68–0.77) 4 0.78 (0.76–0.81)
4–5 0.77 (0.72–0.83) 5 0.78 (0.76–0.80)
>5 0.76 (0.69–0.85) 6 0.78 (0.76–0.80)
Overall 0.78 (0.76–0.80) Mean 5.1 0.78 (0.76–0.80)
CI, confidence interval; CARE, Cholesterol And Recurrent Events; FOURIER, Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated
Risk; HPS, Heart Protection Study; PROVE-IT, Pravastatin or Atorvastatin Evaluation and Infection Therapy; 4S, Scandinavian Simvastatin Survival Study; WOSCOPS, West of
Scotland Coronary Prevention Study.
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The remit for this European Society of Cardiology/European
Atherosclerosis Society (ESC/EAS) Task Force is to consider the im-
pact of this new evidence on recommendations for practical guidance
for the use of PCSK9 inhibitors in clinical practice. While the scientific
evidence for PCSK9 inhibition reducing nonfatal cardiovascular out-
comes in ASCVD patients with LDL-C levels >1.8 mmol/L (70 mg/dL)
at baseline is strong,1 this Task Force also recognizes that the afford-
ability of this treatment varies between countries. What is new to this
updated Task Force guidance is inclusion of (i) an appraisal of recent
cardiovascular outcomes data for PCSK9 monoclonal antibody ther-
apy in the context of the clinical benefit observed with statin therapy
and by duration of therapy; (ii) new clinical decision algorithms, which
differentiate three LDL-C thresholds for consideration of PCSK9 in-
hibitor therapy; (iii) indices of increased cardiovascular risk including
imaging relevant for patient risk stratification; and (iv) discussion of re-
maining gaps in evidence concerning PCSK9 inhibitor therapy. The
LDL-C threshold values were based on consideration of absolute car-
diovascular risk and the absolute LDL-C reduction required, key de-
terminants of absolute cardiovascular risk reduction as supported by
evidence from the CTT Collaboration,4 as well as the magnitude of
LDL-C reduction to be expected with PCSK9 inhibition. Thus, the se-
lected LDL-C thresholds identify patients at high absolute risk with
substantially elevated LDL-C levels despite statin with or without eze-
timibe therapy, who are likely to derive maximum benefit from the ad-
dition of a PCSK9 inhibitor and attain LDL-C goal as a consequence of
at least 50% lowering of LDL-C levels. A summary of terms used in
this document is provided in Box 2.1,6,7,15–17 This document provides
guidance for clinicians in identifying those very high risk patients with
substantially elevated LDL-C levels who are likely to benefit most
from treatment with a PCSK9 inhibitor, taking into account cost issues.
Defining patients considered for
treatment with a proprotein
convertase subtilisin/kexin type 9
inhibitor
On the basis of currently available evidence, this Task Force recom-
mends that a PCSK9 inhibitor should be considered in the following
patient groups.
• Patients with ASCVD, by definition at very high risk,6,7 who have
substantially elevated LDL-C levels despite maximally tolerated
statin with or without ezetimibe therapy, and thus are considered
at particularly high risk of an adverse prognosis.
• Patients with ASCVD and at very high risk who do not tolerate
appropriate doses of at least three statins and thus have elevated
LDL-C levels.
• Familial hypercholesterolaemia patients without clinically diagnosed
ASCVD, at high or very high cardiovascular risk, and with substan-
tially elevated LDL-C levels despite maximally tolerated statin plus
ezetimibe therapy.
Patients with clinical atherosclerotic
cardiovascular disease
As exemplified by FOURIER, patients with documented clinical
ASCVD are at very high cardiovascular risk, with an annual absolute
risk of a major cardiovascular event >3%.1,16 The recommended first
approach to the management of elevated LDL-C levels in these pa-
tients is intense statin therapy.7 Clinicians should allow sufficient time
to achieve the maximum tolerated regimen of statin therapy with
concomitant ezetimibe, depending on clinical judgement and local
guidance.18 Since all statins, as well as ezetimibe, will be available as
generic treatment before mid-2018, it is reasonable to strive for in-
tense statin therapy with ezetimibe in all ASCVD patients. The Task
Force does, however, recognize that while add-on ezetimibe pro-
vides a further 19–23% reduction in LDL-C levels,19,20 this may be in-
sufficient in very high risk patients who typically require more than
50% reduction to attain the recommended LDL-C goal.7
In these very high risk patients, this Task Force recommends an
LDL-C threshold for consideration of PCSK9 inhibitor treatment
of >3.6 mmol/L (140 mg/dL), despite statin with or without ezetimibe
therapy or inability to tolerate appropriate doses of at least three sta-
tins. Reduction of LDL-C levels by 50% with this treatment offers the
possibility of attainment of the guideline-recommended LDL-C goal
(<1.8 mmol/L or 70 mg/dL), resulting in >1% annual reduction in ab-
solute cardiovascular risk.16 The mode of action of a PCSK9 inhibitor
is complementary to statin and ezetimibe (Figure 2). The Task Force
recognizes that the presence of additional indices of risk severity,
such as rapidly progressive ASCVD, in particular after an acute coro-
nary syndrome, diabetes mellitus, or complex multivessel or polyvas-
cular atherosclerotic disease, exacerbates absolute risk.6,21Therefore,
a lower LDL-C threshold is recommended for consideration of
PCSK9 inhibition (>2.6 mmol/L or 100 mg/dL) in these patients
(Figure 3).
It is important to bear in mind that ASCVD patients often have
multiple vascular territories affected and thus have poorer outcome,
requiring more intense treatment.22,23 Where available in routine
practice, imaging may help to identify those patients with severe and/
or extensive ASCVD who are at particularly high risk. Simple non-
invasive measures could be used to assess generalized large vessel
atherosclerosis. Carotid artery scanning, usually ultrasound assessment,
is used for diagnosis of carotid artery plaque (defined as either focal
wall thickening > 50% compared with the surrounding vessel wall or a
focal region with an intima-media thickness measurement >_1.5 mm).6
Coronary calcium score provides a global measure of coronary athero-
sclerosis and a score of >400 reflects significant and possibly high-risk
CAD.24 Coronary computed tomography angiography (CTA) directly
visualizes the extent, severity, location, and composition of coronary
atherosclerosis. Various characteristics on coronary CTA may be help-
ful in identifying high-risk patients (Box 3).25,26 In addition, colour
Doppler scanning of carotid vessels and more complex magnetic reso-
nance angiography imaging can be used to confirm ASCVD in the ca-
rotid or peripheral arteries, as well as to detect renal artery stenosis.6
• A PCSK9 inhibitor should be considered in ASCVD patients
with substantially elevated LDL-C levels despite maximally tol-
erated statin with or without ezetimibe therapy, or inability to
tolerate appropriate doses of at least three statins, especially if
there are additional indices of risk severity, i.e. familial hyper-
cholesterolaemia, multivessel, or polyvascular disease or with
rapidly progressive ASCVD (refer to Figure 3).
4 U. Landmesser et al.
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Familial hypercholesterolaemia patients
without clinically diagnosed
atherosclerotic cardiovascular disease
In routine clinical practice, FH is typically diagnosed using approaches
such as the Dutch Lipid Clinic Network criteria based on familial or
personal history of premature ASCVD, clinical signs such as tendon
xanthoma or corneal arcus, and elevated LDL-C levels, with or with-
out genetic testing, as recommended in the previous Task Force
statement.12 The elevated cardiovascular risk of undertreated het-
erozygous FH patients is well recognized,27–30 with up to eight-fold
higher risk in patients with an FH-causative mutation compared with
unaffected relatives.28 Furthermore, despite long-term, high-intensity
statin treatment to lower LDL-C levels, asymptomatic FH patients of-
ten have evidence of an increased plaque burden in multiple vascular
territories.31As there are no clinical outcomes studies specifically in
FH patients, estimates of absolute cardiovascular risk are based on
data from clinical trials and registries such as the Spanish
SAFEHEART registry.17,32 With maximally tolerated statin therapy
plus ezetimibe (the recommended treatment in FH),7,27 annual car-
diovascular event rates are estimated at 1%, increasing with the pres-
ence of additional risk factors (such as marked hypertension,
smoking, lipoprotein(a) >50 mg/dL, and the presence of premature
cardiovascular disease in first-degree relatives).17
Treatment decisions are currently guided by the LDL-C level and
the presence of additional indices of risk severity.12 Clinicians should
....................................................................................................................................................................................................................
Box 2 Glossary of terms
Term Explanation
Additional indices
of risk severity
Markers of increased cardiovascular risk severity. These are defined for patients with clinical ASCVD as the concomitant pres-
ence of FH; diabetes mellitus with target organ damage or with a major risk factor such as marked hypertension; severe or
extensive ASCVD; or rapid progression of ASCVD (repeated acute coronary syndrome, unplanned coronary revasculariza-
tions or ischaemic stroke within 5 years of the event). These definitions are derived from the 6th Joint Societies Guidelines
for Prevention of CVD,6 the 2016 ESC/EAS Guidelines for Management of Dyslipidaemia,7 and the 2013 ESH/ESC
Guidelines for the Management of Arterial Hypertension.15
For FH patients without clinical ASCVD, additional indices of risk severity are diabetes mellitus with target organ damage or
with a major risk factor such as marked hypertension; lipoprotein(a) >50 mg/dL; major risk factors such as smoking, marked
hypertension; >40 years without treatment; premature ASCVD (<55 years in males and <60 years in females) in first degree
relatives; and imaging indicators of increased risk. These definitions are derived from the 6th Joint Societies Guidelines for
Prevention of CVD,6 the 2016 ESC/EAS Guidelines for Management of Dyslipidaemia,7 the 2013 ESH/ESC Guidelines for the
Management of Arterial Hypertension,15 and the SAFEHEART registry database.17
Clinical benefit This is defined as reduction in major cardiovascular events, the primary endpoint of the FOURIER study,1 a composite of car-
diovascular death, MI, stroke, hospitalization for unstable angina, or coronary revascularization. In FOURIER, clinical benefit
was attributable to reduction in non-fatal events, largely driven by decreases in nonfatal MI and coronary revascularization.
LDL-C goal This is the aim of therapeutic intervention, as recommended by the 6th Joint Societies Guidelines for Prevention of CVD,6 and
the 2016 ESC/EAS Guidelines for Management of Dyslipidaemia.7
LDL-C threshold This is the starting LDL-C value on which treatment decisions for a PCSK9 inhibitor are based, in patients on statin with or
without ezetimibe treatment.
LDL-C threshold in
ASCVD patients
In patients with clinical ASCVD the LDL-C threshold has been defined as > 3.6 mmol/L (140 mg/dL); reduction of LDL-C levels
by 50% offers the possibility of attainment of the guideline-recommended LDL-C goal (70 mg/dL),6,7 and >1% annual reduc-
tion in absolute cardiovascular risk.16 The LDL-C threshold is lower (>2.6 mmol/L or 100 mg/dL) in ASCVD patients with
additional indices of risk severity, defined by the 6th Joint Societies Guidelines for Prevention of CVD,6 and the 2016 ESC/
EAS Guidelines for Management of Dyslipidaemia,7 as the absolute risk of a recurrent event is higher.
LDL-C threshold in FH
patients without
ASCVD
In FH patients without clinical ASCVD the LDL-C threshold has been defined as > 4.5 mmol/L (180 mg/dL); reduction of LDL-
C by at least 50% offers the possibility of attainment of the guideline-recommended LDL-C goal (<2.6 mmol/L or 100 mg/
dL). As shown by the 2016 ESC/EAS Guidelines for Management of Dyslipidaemia,7 and the SAFEHEART Registry,17 FH pa-
tients with additional indices of risk severity are at higher absolute risk. Consequently in these patients, the LDL-C threshold
has been set lower (>3.6 mmol/L or 140 mg/dL).
Very high risk Very high risk patients are defined by the 6th Joint Societies Guidelines for Prevention of CVD,6 and the 2016 ESC/EAS
Guidelines for Management of Dyslipidaemia,7 as those patients with documented ASCVD (clinical or unequivocal on imag-
ing, with plaque on coronary angiography or carotid ultrasound), including those with progressive ASCVD (i.e. repeated
acute coronary syndromes, repeated unplanned coronary revascularizations, or repeated ischaemic strokes within 5 years of
the index event), or diabetes mellitus with target organ damage or with a major risk factor such as marked hypercholestero-
laemia or marked hypertension.
ASCVD, atherosclerotic cardiovascular disease; CVD, cardiovascular disease; EAS, European Atherosclerosis Society; ESC, European Society of Cardiology; ESH, European
Society of Hypertension; FH, familial hypercholesterolaemia; FOURIER, Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk;
LDL-C, low-density lipoprotein cholesterol; MI, myocardial infarction.
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Figure 3 Clinical decision algorithm for the use of a PCSK9 inhibitor in patients with atherosclerotic cardiovascular disease (ASCVD) and with sub-
stantially elevated low-density lipoprotein cholesterol (LDL-C) levels despite maximally tolerated statin with or without ezetimibe therapy. Refer to
Box 2 for the rationale for selection of LDL-C thresholds. Note: Marked hypertension is defined by a blood pressure >_160/100 mmHg, in accordance
with 2013 ESH/ESC guidelines for the management of arterial hypertension.15 The use of add-on ezetimibe is recommended according to clinical
judgement and local guidance. ACS, acute coronary syndrome; CAD, coronary artery disease; PAD, peripheral artery disease.
Figure 2 The modes of action of PCSK9 monoclonal antibody therapy, statin and ezetimibe are complementary. The low-density lipoprotein receptor
(LDLR) at the hepatocyte surface binds circulating LDL particles; the LDLR-LDL complex is then internalized by endocytosis within clathrin-coated vesi-
cles. Internalization of the LDLR, separation from bound LDL in the endosome complex and subsequent recycling of the LDLR to the plasma membrane
is a continuous process (see inset).The level of expression of the LDLR gene (and thus LDLR activity) is sensitive to intracellular cholesterol levels; when
cellular cholesterol levels are low, for example, as a result of statin-mediated inhibition of hepatic cholesterol synthesis, or as a result of reduced flux of chy-
lomicron cholesterol from the intestine to the liver subsequent to ezetimibe-mediated inhibition of cholesterol absorption through the Niemann Pick C1-
like 1 protein (NPC1L1) on the jejunal enterocyte brush border, then LDLR expression is upregulated by the sterol regulatory element binding transcrip-
tion factor 2 (SREBP2). Expression of the PCSK9 gene is equally upregulated by SREBP2. Circulating PCSK9 interacts with and promotes cellular degrada-
tion of the LDLR with reduced LDLR recycling to the hepatocyte membrane; this results in reduced availability of LDLR, leading to higher plasma levels of
LDL cholesterol (LDL-C). By binding to free circulating PCSK9, PCSK9 monoclonal antibodies prevent the association between PCSK9 and LDLR, result-
ing in enhanced recycling, increased LDLR availability and reduced plasma LDL-C levels. Thus, inhibition of HMG-CoA reductase (3-hydroxy-3-methyl-glu-
taryl-coenzyme A reductase) by statins, inhibition of intestinal cholesterol absorption by ezetimibe, and PCSK9 inhibition by monoclonal antibodies,
exhibit complementary mechanisms of action and can be used in combination for highly efficacious lipid lowering therapy.
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make every effort to ensure achievement of the maximally tolerated
statin dose regimen plus ezetimibe, in accordance with current guid-
ance.18 Imaging may also have a role in guiding therapy, as evidence of
increased plaque burden with ultrasound evaluation or CTA has
been shown to be indicative of premature ASCVD and high risk for
cardiovascular events.33,34
Taking account of recent evidence from SAFEHEART,17 this Task
Force recommends that an LDL-C threshold of >4.5 mmol/L
(180 mg/dL) despite maximally tolerated statin plus ezetimibe identi-
fies patients at high risk likely to derive maximum benefit from
PCSK9 inhibition. A lower LDL-C threshold (>3.6 mmol/L
or >140 mg/dL) is recommended when patients have additional indi-
ces of risk severity, as identified in Box 2 and in Figure 4.6,17 This ap-
proach can reduce the need for lipoprotein apheresis, a costly and
invasive procedure which is inconvenient to patients and their carer-
givers.35
As in the previous Task Force document, evolocumab is recom-
mended as an additional therapeutic option to reduce LDL-C levels
in patients with homozygous FH, with or without apheresis. Given
the mode of action of PCSK9 inhibition, some level of LDL receptor
activity is required for efficacy. Consequently, treatment with a
PCSK9 inhibitor is not recommended in patients with negative/nega-
tive LDLR mutations which have LDL receptor activity below 2%, as
supported by evidence from the TESLA B and TAUSSIG stud-
ies.12,36,37 With the very high risk of these patients due to the cumula-
tive burden of very high LDL-C levels, most are likely to have already
experienced clinical events.
• A PCSK9 inhibitor may be considered in heterozygous FH pa-
tients without clinically diagnosed ASCVD with substantially el-
evated LDL-C levels despite maximally tolerated statin plus
ezetimibe therapy.
• The LDL-C threshold for consideration of PCSK9 inhibition is
lower if there are additional indices of risk severity (refer to
Figure 4).
Monitoring low-density lipoprotein
cholesterol lowering response
Response to initiation or dose adjustment of lipid lowering treatment
(statin or add-on ezetimibe) can be assessed at 4 weeks.7 As a
minimum, LDL-C levels should be monitored, but a comprehensive
lipid profile may facilitate better management decisions, given effects
on triglycerides (median reduction 16%) and high-density lipopro-
tein cholesterol (mean increase 5%) observed with evolocumab in
FOURIER.1 Failure to attain LDL-C goal may be due to a number of
factors including pharmacogenetic effects associated with reduced
responsiveness, an inability to tolerate adequate statin doses and lack
of adherence.7,12 Consequently, if the patient is not at LDL-C goal on
maximally tolerated statin therapy, adherence should be first checked
and the clinician should reinforce the importance of treatment com-
pliance as a determinant of improved cardiovascular outcome.38 If ad-
herence is shown to be satisfactory, the clinician should consider
add-on ezetimibe treatment, in accordance with local guidance. If af-
ter 4 weeks the LDL-C lowering response is still inadequate and the
patient is adherent with treatment, addition of a PCSK9 inhibitor
should be considered (Figure 5).
Following a single injection of alirocumab or evolocumab, complete
PCSK9 inhibition occurs rapidly and is sustained for 3–4 days with the
nadir in LDL-C lowering response at 11–15 days.39,40 This response is
similar for either regimens of alirocumab (75/150 mg every 2 weeks) or
evolocumab (140 mg every 2 weeks or 420 mg every month).41
Information documenting the inter-individual variability in the LDL-C
lowering response to PCSK9 inhibition is, as yet, limited. This is a perti-
nent issue, in the light of evidence from the SPIRE programme, in which
the development of antidrug antibodies in a proportion of patients was
associated with loss of LDL-C lowering efficacy and no cardiovascular
benefit, as opposed to a significant cardiovascular benefit in patients
who did not develop antidrug antibodies and had a persistent LDL-C
lowering response (see Box 1).3 There are limited data for alirocumab
or evolocumab. In an analysis of trial data from more than 4700 patients
treated with alirocumab for up to 78 weeks, 1.2% of patients developed
persistent antidrug antibodies with the 150 mg 2-weekly regimen and
1.8% with the 75/150 mg 2-weekly regimen.42 Antidrug antibodies
were developed by 0.3% of patients allocated to evolocumab in
FOURIER, and 0.3% (4 patients) in the Open Label Study of Long Term
Evaluation Against LDL-C Trial (OSLER-1) extension study (two pa-
tients each who were initially allocated to standard of care
or evolocumab, and then received the alternative treatment dur-
ing long-term follow-up).1,14 In the absence of extensive documentation
of variability in the inter-individual response, this Task Force recom-
mends that clinicians should monitor the LDL-C lowering response to
alirocumab or evolocumab as indicated below and in Figure 5.
• Monitor the LDL-C lowering response to statin and ezetimibe
at 4 weeks and check adherence before considering a PCSK9
inhibitor.
• Assess the LDL-C lowering response to the PCSK9 inhibitor
at 2 weeks after first injection of either the monthly or 2-
weekly regimen (before the next injection).
Future perspectives and gaps in
knowledge
Despite this new evidence from the FOURIER and SPIRE trials, gaps
remain in our knowledge regarding the use of PCSK9 inhibition in
clinical practice (Box 4). The Evaluation of Cardiovascular Outcomes
Box 3 Markers of high risk with coronary computed
tomography angiography (CTA)
Global high-risk markers on coronary CTA:
• Left main disease
• Proximal LAD disease
• 3-vessel disease
Focal high-risk markers on coronary CTA:
• Stenosis severity: >50% luminal obstruction
• Lesion composition: Mixed or non-calcified (reflecting earlier, unsta-
ble atherosclerosis)
CTA, computed tomography angiography; LAD, left anterior descending artery.
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Figure 4 Clinical decision algorithm for the use of a PCSK9 inhibitor in familial hypercholesterolaemia patients without clinically diagnosed athero-
sclerotic cardiovascular disease (ASCVD) and with substantially elevated low-density lipoprotein cholesterol (LDL-C) levels despite maximally toler-
ated statin plus ezetimibe therapy. Refer to Box 2 for the rationale for selection of LDL-C thresholds. Note: Marked hypertension is defined by a
blood pressure >_160/100 mmHg, in accordance with 2013 ESH/ESC guidelines for the management of arterial hypertension.15
Figure 5 Monitoring the low-density lipoprotein cholesterol (LDL-C) lowering response to statin, ezetimibe and a PCSK9 inhibitor. Note: LDL-C
goal is the aim of therapeutic intervention, with LDL-C levels as recommended by the 6th Joint Societies Guidelines for Prevention of Cardiovascular
Disease,6 and the 2016 ESC/EAS Guidelines for Management of Dyslipidaemia.7 In contrast, LDL-C threshold is the starting LDL-C value on which
treatment decisions for a PCSK9 inhibitor are based, in patients on statin plus ezetimibe treatment (Box 2).
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After an Acute Coronary Syndrome During Treatment With
Alirocumab (ODYSSEY Outcomes) trial will provide additional infor-
mation in patients treated with a PCSK9 inhibitor within 1–12 months
(median 2.6 months, interim data) of an acute coronary
syndrome.43,44
As with all novel treatments, long-term safety remains to be estab-
lished. To date there are exposure data for up to 4 years’ treatment
with a PCSK9 inhibitor, including patients with heterozygous FH, pre-
dominantly involving a background of concomitant statin ther-
apy.14,45,46 Potential injection site reactions occurred in <5% of
patients, and were mainly of very mild intensity with no evidence of a
cumulative effect. When the PCSK9 inhibitor was compared with
standard of care (statin with or without ezetimibe), annualized event
rates for muscle symptoms, (4.7% vs. 8.5% with standard of care),
and new-onset diabetes (2.8% vs. 4.0%, respectively) appear similar;
Mendelian randomization studies do, however, indicate a potential
risk for diabetes.5,14 Clearly, there is a need for longer observation to
assess potential effects on glucose control. There is no evidence to
suggest an increase in the risk of haemorrhagic stroke with the addi-
tion of a PCSK9 inhibitor to statin treatment, as the point estimate of
evolocumab compared with usual care (statin) reported in FOURIER
was similar to that observed in the CTT meta-analysis of statin vs. pla-
cebo monotherapy trials.1,4
The safety of very low LDL-C levels merits special consideration,
given that one in four patients treated with evolocumab in FOURIER
attained LDL-C levels less than 0.52 mmol/L or 20 mg/dL.1 Evidence
to date, including patients with rare genetic traits associated with
very low LDL-C levels, suggests no detrimental impact on steroid
hormone production, enterohepatic circulation of bile acids, or neu-
ronal cell function.47 Indeed, these LDL-C levels are also consistent
with the very low levels observed in newborns which, despite the
physiological and developmental demands of infancy, are compatible
with normal development.48
Irrespective of diabetes status at baseline, very low LDL-C levels
(less than 0.65 mmol/L or 25 mg/dL) with alirocumab did not appear
to affect mean glycated haemoglobin levels over time. There was also
no excess risk for diabetes in patients with LDL-C levels <0.65 mmol/
L.47 Similar findings were reported with evolocumab.14 Additionally,
in patients with diabetes mellitus treated with insulin, there was no
change in glycated haemoglobin or fasting plasma glucose during alir-
ocumab treatment.49 As previously discussed, however, Mendelian
randomization studies indicate an increase in lifetime risk for diabetes
with carriage of PCSK9 loss-of-function variants.5 Clearly, this ques-
tion will have to be evaluated further with additional large-scale trial
data over a longer observation period.
Additionally, data from the ODYSSEY and PROFICIO pro-
grammes, FOURIER and 6-year follow-up from the Improved
Reduction of Outcomes: Vytorin Efficacy International Trial
(IMPROVE-IT) showed no increase in adverse events including se-
vere muscle symptoms, liver enzyme elevation, cognitive adverse
events, or haemorrhagic stroke with very low LDL-C levels.1,13,46
The Evaluating PCSK9 Binding antiBody Influence oN coGnitive
HeAlth in High cardiovascUlar Risk Subjects (EBBINGHAUS) trial, a
substudy of FOURIER in 1204 patients (mean age 63 years), specifi-
cally evaluated effects on cognitive function using a robust well-
validated testing platform [Cambridge Neuropsychological Test
Automated Battery (CANTAB) Assessment]. This study showed no
detriment, even in patients attaining LDL-C levels <0.65 mmol/L
(<25 mg/dL).50 Long-term evaluation, especially in older patients
(>75 years), is nonetheless warranted.
• In summary, this Task Force concludes that the available
limited evidence for the safety of PCSK9 inhibition, and
specifically for very low LDL C levels attained on treat-
ment, is reassuring although further long-term surveillance
is clearly indicated.
Health economics
The introduction of innovative therapeutic agents for the treatment
of chronic disease states in large patient populations has important
health economic implications. Patient groups at very high cardiovas-
cular risk are likely to be a priority for treatment, although access is
ultimately determined by the societal willingness-to-pay threshold
based on quality-adjusted life-years gained.
Detailed discussion of cost-effectiveness analyses of PCSK9 inhibi-
tion in the proposed priority groups is beyond the remit of this Task
Force. While some have concluded that the cost of treatment far ex-
ceeds the societal willingness - to - pay threshold,51 others have ar-
gued that about one-half of this cost would be saved by reduction in
direct and indirect disease-related costs.52 It is important to bear in
mind that absolute cardiovascular risk together with absolute LDL-C
levels are the key determinants of the number needed to treat
(NNT) to prevent a cardiovascular event. In patients with ASCVD,
who have substantially elevated LDL-C levels despite maximally tol-
erated statin plus ezetimibe therapy, or inability to tolerate statins,
data from FOURIER suggest that adding a PCSK9 inhibitor to lower
LDL-C levels by 50% might be expected to reduce the 5-year
Box 4 Gaps in knowledge concerning proprotein con-
vertase subtilisin/kexin type 9 (PCSK9) inhibitor
therapy
• Inter-individual variability in low-density lipoprotein cholesterol
(LDL-C) lowering response to alirocumab and evolocumab
• Dedicated trials in patients with recent (<1 month) cardiovascular
events
• Impact of PCSK9 inhibition in patients with chronic kidney disease
(not requiring dialysis)
• Long-term efficacy and safety of PCSK9 inhibitors in clinical use
• Long-term safety of very low LDL-C levels
• Long-term impact of PCSK9 inhibition on disability and cardiovascu-
lar mortality
• Long-term evaluation of risk for type 2 diabetes
• Impact of sustained and marked LDL-C lowering to very low levels
on plaque composition and stability
• Long-term impact of reduction in elevated lipoprotein(a) with
PCSK9 inhibition
• Cost-effectiveness of PCSK9 inhibition added to maximally tolerated
statin with or without ezetimibe therapy.
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NNT to <_30 in patients with a baseline LDL-C >3.6 mmol/L
(140 mg/dL).1,16 Bearing in mind evidence of a continued or legacy
benefit from 5 years treatment with a statin in the West of Scotland
Coronary Prevention Study,53 however, it would be presumptive to
model the impact of adding a PCSK9 inhibitor on the NNT until
longer-term follow-up data are available to assess the potential of
these treatments to modify the trajectory of ASCVD.
Recommendations for cost-effectiveness analysis relating to the judi-
cious use of innovative treatments are also evolving.54 As highlighted by
the EAS Consensus Panel Statement on LDL causality, the impact of
therapy on lifetime cardiovascular risk also needs to be considered.11
Prioritizing the use of a PCSK9 inhibitor in the very high risk patient
groups defined in this Task Force statement, with substantially elevated
LDL-C levels despite maximally tolerated statin wth or without ezeti-
mibe therapy or inability to tolerate statins, may therefore have the po-
tential to be cost efficient. Obviously, as these patients typically have
multiple risk factors beyond elevated LDL-C, incorporation of simple
preventive strategies, such as lifestyle interventions, smoking cessation,
and blood pressure control, which have additive effects, is essential.
Conclusions
Having appraised the evidence from the first of the cardiovascular
outcomes studies with PCSK9 inhibitors, this Task Force concludes
that addition of a PCSK9 inhibitor should be considered in patients
with ASCVD, and in FH patients without a prior clinical event, who
have substantially elevated LDL-C levels despite maximally tolerated
statin with or without ezetimibe therapy, or inability to tolerate ap-
propriate doses of at least three statins (Summary Figure). Low levels
of LDL-C attained on a PCSK9 inhibitor appear to be safe within the
observation period of clinical trials performed so far. Prioritizing the
use of this efficacious therapy in these patient groups may help re-
duce cardiovascular outcomes and the impact of the associated phys-
ical and/or psychological disability.
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